Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732807 · ClinicalTrials.gov registry record · Phase 2
PF-06651600 for the Treatment of Alopecia Areata
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 718
- Enrollment target
NCT03732807 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 718 participants.
The verdict
NCT03732807, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 718 participants
- Enrollment target
Study Summary
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Interventions
- DRUG Placebo
- DRUG PF-06651600 Induction Dose
- DRUG PF-06651600 Maintenance Dose #1
- DRUG PF-06651600 Maintenance Dose #2
- DRUG PF-06651600 Maintenance Dose #3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732807
The ClinicalTrials.gov registry entry for NCT03732807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 718 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03732807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03732807 about?
NCT03732807 is a clinical study titled "PF-06651600 for the Treatment of Alopecia Areata". This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will...
What is the current status of trial NCT03732807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 718 participants. The study started on 2018-12-03. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03732807?
The interventions under investigation include: Placebo (DRUG), PF-06651600 Induction Dose (DRUG), PF-06651600 Maintenance Dose #1 (DRUG), PF-06651600 Maintenance Dose #2 (DRUG), PF-06651600 Maintenance Dose #3 (DRUG).
Who is sponsoring clinical trial NCT03732807?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.